China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $2.32M invested in China SXT Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
46% more capital invested
Capital invested by funds: $1.58M → $2.32M (+$734K)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $1.16M | – | – | – |
|
2
Acadian Asset Management
Boston,
Massachusetts
| $531K | – | – | – |
|
3
Renaissance Technologies
New York
| $490K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $66K | – | – | – |
|
|
HF
5
HRT Financial
New York
| $44K | – | – | – |
|
|
BWA
6
Beam Wealth Advisors
Covington,
Louisiana
| $10K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $10K | – | – | – |
|
8
Citadel Advisors
Miami,
Florida
| $7K | – | – | – |
|
SXTC Hedge Fund Activity: Q2 2020 in Review
1 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2020, worth a combined $2.32M — up 46% from $1.58M a quarter earlier.
Fund positioning in SXTC was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $2.32M of China SXT Pharmaceuticals stock for Q2 2020, up 46% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q2 2020 and 0 closed out.
Based on aggregated 13F filings for Q2 2020.